Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cyproterone acetate versus spironolactone anti-androgen therapy in transgender women
TCTR20190404001Phase 4Not yet recruiting
- Sponsor
- Ratchadaphiseksomphot Endowment Fund
- Start
- Apr 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of cyproterone, spironolactone, estradiol valerate in gender dysphoria (GD), sponsored by Ratchadaphiseksomphot Endowment Fund. Planned start Apr 2019; status: not yet recruiting.
02
Drugs
cyproteronespironolactoneestradiol valerate
03
Conditions
gender dysphoria (GD)
Beyond the preview
Go deeper on TCTR20190404001.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on TCTR20190404001.